GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: An updated meta-analysis

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 32, Issue 7, 2013, Pages 859-868

  Li, C ^a   Long, J ^a   Hu, X ^a   Zhou, Y ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTITUBERCULOSIS DRUG INDUCED HEPATOTOXICITY; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; ETHNICITY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NULL ALLELE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG-INDUCED LIVER INJURY; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE TRANSFERASE; HUMANS; POLYMORPHISM, GENETIC; TUBERCULOSIS;

EID: 84879171907     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-013-1831-y     Document Type: Review

References (52)

1. WHO global tuberculosis control report 2010 (2010) Summary. Cent Eur J Public Health 18:237
2. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA; American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society (2003) American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 167:603-662
3. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998(1998) Joint Tuberculosis Committee of the British Thoracic Society. Thorax 53:536-548
4. Garibaldi RA, Drusin RE, Ferebee SH, Gregg MB (1972) Isoniazid-associated hepatitis. Report of an outbreak. Am Rev Respir Dis 106:357-365
5. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR; ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee (2006) An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174:935-952
6. Acharya SK, Dasarathy S, Kumer TL, Sushma S, Prasanna KS, Tandon A, Sreenivas V, Nijhawan S, Panda SK, Nanda SK, Irshad M, Joshi YK, Duttagupta S, Tandon RK, Tandon BN (1996) Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome. Hepatology 23:1448-1455
7. Grönhagen-Riska C, Hellstrom PE, Fröseth B (1978) Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis 118:461-466
8. Mitchell JR, Zimmerman HJ, Ishak KG, Thorgeirsson UP, Timbrell JA, Snodgrass WR, Nelson SD (1976) Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 84:181-192
9. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R (2008) Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 23:192-202
10. Naisbitt DJ, Williams DP, Pirmohamed M, Kitteringham NR, Park BK (2001) Reactive metabolites and their role in drug reactions. Curr Opin Allergy Clin Immunol 1:317-325
11. Meister A (1983) Selective modification of glutathione metabolism. Science 220:472-477
12. Meister A, Anderson ME (1983) Glutathione. Annu Rev Biochem 52:711-760
13. Andreoli SP, Mallett CP, Bergstein JM (1986) Role of glutathione in protecting endothelial cells against hydrogen peroxide oxidant injury. J Lab Clin Med 108:190-198
14. Mitchell JR, Jollow DJ, Potter WZ, Gillette JR, Brodie BB (1973) Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther 187:211-217
15. Fontana X, Peyrottes I, Rossi C, Leblanc-Talent P, Ettore F, Namer M, Bussière F (1998) Study of the frequencies of CYP1A1 gene polymorphisms and glutathione S-transferase mu1 gene in primary breast cancers: an update with an additional 114 cases. Mutat Res 403:45-53
16. Hussey AJ, Stockman PK, Beckett GJ, Hayes JD (1986) Variations in the glutathione S-transferase subunits expressed in human livers. Biochim Biophys Acta 874:1-12
17. Meyer DJ, Coles B, Pemble SE, Gilmore KS, Fraser GM, Ketterer B (1991) Theta, a new class of glutathione transferases purified from rat and man. Biochem J 274(Pt 2):409-414
18. Roy B, Chowdhury A, Kundu S, Santra A, Dey B, Chakraborty M, Majumder PP (2001) Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J Gastroenterol Hepatol 16:1033-1037
19. Sun F, Chen Y, Xiang Y, Zhan S (2008) Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 12:994-1002
20. Cai Y, Yi J, Zhou C, Shen X (2012) Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. PLoS One 7:e47769
21. Rana SV, Sharma SK, Ola RP, Sinha SK, Arora SK, Singh K (2012) Antitubercular treatment induced hepatotoxicity in north Indians - role of glutathione-S-transferase, N-acetyltransferase2 and cytochrome P4502E1 gene polymorphisms. J Clin Exp Hepatol 2:S36-S37
22. Monteiro TP, El-Jaick KB, Jeovanio-Silva AL, Brasil PE, Costa MJ, Rolla VC, de Castro L (2012) The roles of GSTM1 and GSTT1 null genotypes and other predictors in anti-tuberculosis drug-induced liver injury. J Clin Pharm Ther 37:712-718
23. Petitti DB (2000) Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine, 2nd edn. Oxford University Press, New York
24. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188
25. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F (2000) Methods for meta-analysis in medical research. Wiley, Chichester
26. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101-129
27. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560
28. Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127:820-826
29. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101
30. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634
31. Forestiero FJ, Cecon L, Hirata MH, de Melo FF, Cardoso RF, Cerda A, Hirata RD (2013) Relationship of NAT2, CYP2E1 and GSTM1/GSTT1 polymorphisms with mild elevation of liver enzymes in Brazilian individuals under anti-tuberculosis drug therapy. Clin Chim Acta 415:215-219
32. Costa GN, Magno LA, Santana CV, Konstantinovas C, Saito ST, Machado M, Di Pietro G, Bastos-Rodrigues L, Miranda DM, De Marco LA, Romano-Silva MA, Rios-Santos F (2012) Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs. Mol Diagn Ther 16:241-250
33. Huang YS (2007) Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury. Expert Opin Drug Metab Toxicol 3:1-8
34. Wang J, Deng Y, Li L, Kuriki K, Ding J, Pan X, Zhuge X, Jiang J, Luo C, Lin P, Tokudome S (2003) Association of GSTM1, CYP1A1 and CYP2E1 genetic polymorphisms with susceptibility to lung adenocarcinoma: a case-control study in Chinese population. Cancer Sci 94:448-452
35. Wang T, Yu HX, Wang W, Pan YY, He LX, Wang ZY (2011) Association of GSTM1 genetic polymorphisms with susceptibility to antituberculosis drug induced hepatotoxicity, a study in Chinese population. Chin J Med Guide 13:2164-2165
36. Huang YS, Su WJ, Huang YH, Chen CY, Chang FY, Lin HC, Lee SD (2007) Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 47:128-134
37. Teixeira RL, Morato RG, Cabello PH, Muniz LM, Moreira Ada S, Kritski AL, Mello FC, Suffys PN, Miranda AB, Santos AR (2011) Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem Inst Oswaldo Cruz 106:716-724
38. Chatterjee S, Lyle N, Mandal A, Kundu S (2010) GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs. J Clin Pharm Ther 35:465-470
39. Leiro V, Fernández-Villar A, Valverde D, Constenla L, Vázquez R, Piñeiro L, González-Quintela A (2008) Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int 28:835-839
40. Tang SW, Lv XZ, Zhang Y, Wu SS, Yang ZR, Xia YY, Tu DH, Deng PY, Ma Y, Chen DF, Zhan SY (2012) CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study. J Clin Pharm Ther 37:588-593
41. Wang T, Yu HT, Wang W, Pan YY, He LX, Wang ZY (2010) Genetic polymorphisms of cytochrome P450 and glutathione S-transferase associated with antituberculosis drug-induced hepatotoxicity in Chinese tuberculosis patients. J Int Med Res 38:977-986
42. Zhu DL, Xi Y, Wu XQ (2011) Relationship between genetic polymorphisms of GSTM1, GSTT1 and the susceptibility to antituberculosis drug-induced liver injury. Zhongguo Kang Sheng Su Za Zhi 36:864-868
43. Kim SH, Kim SH, Yoon HJ, Shin DH, Park SS, Kim YS, Park JS, Jee YK (2010) GSTT1 and GSTM1 null mutations and adverse reactions induced by antituberculosis drugs in Koreans. Tuberculosis (Edinb) 90:39-43
44. Sotsuka T, Sasaki Y, Hirai S, Yamagishi F, Ueno K (2011) Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients. In Vivo 25:803-812
45. Guo M, Sun YH, Li SM, Wang D, Liu Q, Zhang XY, Liu XX, Feng FM (2009) The effect of GST M1 and GST T1 gene mutations on anti-tuberculous drug induced hepatic injury. Zhonghua Jie He He Hu Xi Za Zhi 32:266-269
46. Imanishi H, Okamura N, Yagi M, Noro Y, Moriya Y, Nakamura T, Hayakawa A, Takeshima Y, Sakaeda T, Matsuo M, Okumura K (2007) Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet 52:166-171
47. Watanabe I, Tomita A, Shimizu M, Sugawara M, Yasumo H, Koishi R, Takahashi T, Miyoshi K, Nakamura K, Izumi T, Matsushita Y, Furukawa H, Haruyama H, Koga T (2003) A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther 73:435-455
48. Simon T, Becquemont L, Mary-Krause M, de Waziers I, Beaune P, Funck-Brentano C, Jaillon P (2000) Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther 67:432-437
49. Ueda K, Ishitsu T, Seo T, Ueda N, Murata T, Hori M, Nakagawa K (2007) Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity. Pharmacogenomics 8:435-442
50. Ioannidis JP, Patsopoulos NA, Evangelou E (2007) Uncertainty in heterogeneity estimates in meta-analyses. BMJ 335:914-916
51. Ye Z, Song H (2005) Glutathione s-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukaemia: a systematic review and meta-analysis. Eur J Cancer 41:980-989
52. Garte S (1998) The role of ethnicity in cancer susceptibility gene polymorphisms: the example of CYP1A1. Carcinogenesis 19:1329-1332